ZymoGenetics Reveals Positive Study Results of Melanoma Drug

3 October 2010 (Last Updated October 3rd, 2010 18:30)

ZymoGenetics has revealed the results of its Phase IIa clinical trial of recombinant Interleukin 21 (IL-21) for the treatment of metastatic melanoma. IL-21 is a cytokine that works by activating the body's immune cells to eliminate virally infected or cancerous cells from the body.

ZymoGenetics has revealed the results of its Phase IIa clinical trial of recombinant Interleukin 21 (IL-21) for the treatment of metastatic melanoma.

IL-21 is a cytokine that works by activating the body's immune cells to eliminate virally infected or cancerous cells from the body.

The single-arm, open-label and multicentre study was conducted in Canada and enrolled 40 patients with Stage 4 melanoma, who were given three dosing regimens of IL-21.

The study showed that the median overall survival was 12.4 months, with 53% of the patients surviving at 12 months.

The overall response rate in 39 evaluable patients was 23%, and the median progression-free survival was 4.3 months.